Predict your next investment

Corporation
lifemapsc.com

See what CB Insights has to offer

Investments

1

Partners & Customers

10

About LifeMap Sciences

LifeMap Sciences (LifeMap), is developing a discovery platform, including a web-based database, to aid researchers in the use of embryonic stem cells, progenitor cells, and induced pluripotent stem cells for the development of new products and technologies in the emerging field of regenerative medicine. LifeMap Sciences intends to become the central knowledgebase for stem cell research and discovery of cell-based regenerative medicine therapeutic products. LifeMap SciencesÂ’ core technology and business is based on a state-of-the-art roadmap for stem cell research providing comprehensive coverage of embryonic stem cell biology.

LifeMap Sciences Headquarter Location

1301 Harbor Bay Parkway #100

Alameda, California, 94502,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest LifeMap Sciences News

AgeX Therapeutics Reports Second Quarter 2022 Financial Results

Aug 12, 2022

08/12/2022 | 04:06pm EDT Message : *Required fields AgeX Therapeutics , Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2022. Liquidity and Capital Resources During the first quarter of 2022, AgeX borrowed the final $0.5 million of its available credit under its 2020 Secured Convertible Facility Agreement with Juvenescence Limited (“Juvenescence”), and entered into a new Secured Convertible Promissory Note (the “Secured Note”) pursuant to which Juvenescence has agreed to provide to AgeX a $13,160,000 line of credit for a period of 12 months. AgeX drew an initial $8,160,000 of the line of credit and used $7,160,000 to refinance the principal and the loan origination fees under its 2019 Loan Agreement with Juvenescence. During the three months ended June 30, 2022, AgeX borrowed an additional $2.0 million under the Secured Note, and as of August 12, 2022, AgeX had borrowed at total of $10,160,000 with $3.0 million of funds remaining for future borrowings under the Secured Note. The remaining line of credit available may be drawn down from time to time until February 14, 2023 subject to Juvenescence’s discretion to approve each loan draw. The outstanding principal balance of the Secured Note will become due and payable on February 14, 2024. In addition, AgeX may sell shares of its common stock in “at-the-market” transactions through a Sales Agreement with Chardan Capital, LLC as a sales agent. The market value of common shares that AgeX may sell in any 12 month period during the term of the Sales Agreement will be limited to one-third of aggregate market value of AgeX common stock held by stockholders who would not be considered “affiliates” of AgeX, determined in accordance with applicable SEC rules. Going Concern Considerations As required under Accounting Standards Update 2014-15, Presentation of Financial Statements-Going Concern (ASC 205-40), AgeX evaluates whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date its financial statements are issued. Based on AgeX’s most recent projected cash flows, AgeX believes that its cash and cash equivalents and available sources of debt and equity capital would not be sufficient to satisfy AgeX’s anticipated operating and other funding requirements for the twelve months following the filing of AgeX’s Quarterly Report on Form 10-Q for the three and six months ended June 30, 2022. These factors raise substantial doubt regarding the ability of AgeX to continue as a going concern. Balance Sheet Information Second Quarter 2022 Operating Results The following comparisons exclude the impact of the operations of AgeX’s former subsidiary LifeMap Sciences, Inc. (“LifeMap Sciences”) which have been presented in AgeX’s consolidated financial results as discontinued operations for all periods presented due to the disposition of AgeX’s shares of LifeMap Sciences in a cash-out merger during March 2021. Revenues: Total revenues for the second quarter of 2022 were $12,000 as compared with $37,000 for the second quarter of 2021, primarily due to decreased sales of research products and the expiration of a research grant from the NIH that had been available during 2021. Operating expenses: Operating expenses for the three months ended June 30, 2022 were $1.6 million as compared to $2.2 million for the same period in 2021. Research and development expenses decreased to $0.3 million during the three months ended June 30, 2022 from $0.5 million during the same period of 2021 primarily reflecting a reduction of $0.2 million in scientific consulting and outside research and service and patent related expenses under a sponsored research agreement with a university. General and administrative expenses decreased to $1.3 million during the three months ended June 30, 2022 from $1.7 million during the same period in 2021. The $0.4 million decrease is primarily attributable to decreases of $0.1 million in each of the following expense categories: professional fees for legal services, consulting expenses, noncash stock-based compensation expense to directors, and annual minimum royalties due under license agreements. Other expense, net: Total other expense, net for the three months ended June 30, 2022 consists primarily of $0.9 million amortization of deferred debt issuance costs to interest expense and other debt related expenses included in interest expense and $0.2 million unrealized loss on change in fair value of warrants issued to Juvenescence in connection with borrowings under the Secured Note. Total other expense, net for the three months ended June 30, 2021 consists primarily of $0.3 million amortization of deferred debt issuance costs to interest expense. About AgeX Therapeutics AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics to treat human diseases to increase healthspan and combat the effects of aging. AgeX’s PureStem® and UniverCyte™ manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeX’s revolutionary longevity platform induced Tissue Regeneration (iTR™) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. HyStem® is AgeX’s delivery technology to stably engraft PureStem or other cell therapies in the body. AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates. For more information, please visit www.agexinc.com or connect with the company on Twitter , LinkedIn , Facebook , and YouTube . Forward-Looking Statements Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the “Risk Factors” section of AgeX’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at www.sec.gov ). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law. AGEX THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS

LifeMap Sciences Investments

1 Investments

LifeMap Sciences has made 1 investments. Their latest investment was in LifeMap Solutions as part of their Corporate Minority on May 5, 2014.

CBI Logo

LifeMap Sciences Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/7/2014

Corporate Minority

LifeMap Solutions

$5M

Yes

1

Date

5/7/2014

Round

Corporate Minority

Company

LifeMap Solutions

Amount

$5M

New?

Yes

Co-Investors

Sources

1

LifeMap Sciences Acquisitions

1 Acquisition

LifeMap Sciences acquired 1 company. Their latest acquisition was XenneX on April 22, 2012.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

4/22/2012

$99M

Acquired

Date

4/22/2012

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Acquired

Sources

LifeMap Sciences Partners & Customers

10 Partners and customers

LifeMap Sciences has 10 strategic partners and customers. LifeMap Sciences recently partnered with Genomenon on April 4, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

4/2/2019

Partner

United States

ALAMEDA, Calif. and ANN ARBOR, Mich., Apr. LifeMap Sciences and Genomenon Partner to Integrate Mastermind Genomic Search Engine into GeneCards Suite and TGex.

2 , 2019 / PRNewswire-PRWeb / -- LifeMap Sciences , the leading integrated biomedical knowledgebase company and a leading provider of tertiary NGS analysis and interpretation solutions for genetic disorders , and Genomenon , the leading genomic search company , announced today that they have entered into a partnership to improve LifeMap Sciences 's GeneCards knowledgebase and provide accelerated interpretation of genetic disorders by integrating the Mastermind Genomic Search Engine .

1

1/10/2019

Partner

China

LifeMap Sciences Tianjin Novogene and Shanghai Shanyi Announce Strategic Partnership to Offer Leading Clinical NGS Solution to the China Market

The partnership with Novogene Tianjin will allow us to rapidly expand our offerings in the China market , and together to offer best-of-breed end-to-end clinical NGS solutions to the China market . ''

2

1/10/2019

Partner

China

LifeMap Sciences, Tianjin Novogene and Shanghai Shanyi Announce Strategic Partnership to Offer Leading Clinical NGS Solution to the China Market

AgeX Therapeutics , Inc. is aggressively developing its core product pipeline for use in the clinic to extend human healthspan , and is seeking opportunities to form licensing and partnership agreements around its broad IP estate and proprietary technology platforms for non-core clinical applications .

1

1/10/2019

Licensee

China

Subscribe to see more

Subscribe to see more

10

11/29/2018

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

4/2/2019

1/10/2019

1/10/2019

1/10/2019

11/29/2018

Type

Partner

Partner

Partner

Licensee

Partner

Business Partner

Country

United States

China

China

China

United States

News Snippet

ALAMEDA, Calif. and ANN ARBOR, Mich., Apr. LifeMap Sciences and Genomenon Partner to Integrate Mastermind Genomic Search Engine into GeneCards Suite and TGex.

2 , 2019 / PRNewswire-PRWeb / -- LifeMap Sciences , the leading integrated biomedical knowledgebase company and a leading provider of tertiary NGS analysis and interpretation solutions for genetic disorders , and Genomenon , the leading genomic search company , announced today that they have entered into a partnership to improve LifeMap Sciences 's GeneCards knowledgebase and provide accelerated interpretation of genetic disorders by integrating the Mastermind Genomic Search Engine .

LifeMap Sciences Tianjin Novogene and Shanghai Shanyi Announce Strategic Partnership to Offer Leading Clinical NGS Solution to the China Market

The partnership with Novogene Tianjin will allow us to rapidly expand our offerings in the China market , and together to offer best-of-breed end-to-end clinical NGS solutions to the China market . ''

LifeMap Sciences, Tianjin Novogene and Shanghai Shanyi Announce Strategic Partnership to Offer Leading Clinical NGS Solution to the China Market

AgeX Therapeutics , Inc. is aggressively developing its core product pipeline for use in the clinic to extend human healthspan , and is seeking opportunities to form licensing and partnership agreements around its broad IP estate and proprietary technology platforms for non-core clinical applications .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

2

1

10

10

LifeMap Sciences Team

2 Team Members

LifeMap Sciences has 2 team members, including former Chief Executive Officer, President, David Warshawsky.

Name

Work History

Title

Status

David Warshawsky

Theranica, Avraham Pharmaceuticals, Paramount BioSciences, XenneX, Compugen, and University of Massachusetts Amherst

Chief Executive Officer, President

Former

Yaron Mazor

Senior Vice President

Former

Name

David Warshawsky

Yaron Mazor

Work History

Theranica, Avraham Pharmaceuticals, Paramount BioSciences, XenneX, Compugen, and University of Massachusetts Amherst

Title

Chief Executive Officer, President

Senior Vice President

Status

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.